$LSTA

$1.06 +$0.06 (6.44%) Close

$LSTA Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Ownership

13F as of Q2 2026 · 9.0M shares outstanding

Who owns LSTA?

By type of holder

Institutions 13.4% Insiders 11.1% Everyone else 75.5%

Concentration Top 10 holders own 16.0%

Deeter Investments LLP 1.3% · Mazzo David J 3.5%

Institutional ownership

13.4%

-2.2 pts vs last qtr

Institutional holders

-2 vs last qtr

Net shares bought

−201.7K

by institutions in Q2 2026

New / sold out

3 / 5

positions opened vs closed

How is ownership changing?

Institutions, last 8 quarters

Biggest buyers in Q2 2026

Yakira Capital Management, Inc. NEW +138.6K
CSS Llc/il +48.5K

Biggest sellers in Q2 2026

Deeter Investments LLP −245.6K
Renaissance Technologies LLC SOLD OUT −131.7K

Who is planning to sell?

No insider has filed a notice of proposed sale (Form 144) for Lisata Therapeutics Inc in the last 12 months.

Is your stake being diluted?

Diluted share count, FY2021–FY2025

+135.5%

+23.89% a year

Each share's claim on the business

−57.5%

shrank without buying or selling a share

Spent on buybacks vs paid in stock

— vs $4.92M

over 5 fiscal years

Diluted shares, split-adjusted

Buybacks Stock-based comp

How patient are the owners?

Institutional shares by how long they've been held

5+ years0% 3–5 years42% 1–3 years2% Under 1 year56%

Quarterly turnover

25.4%

of institutional shares changed hands

Top 10 managers, median time held

1 quarter

Super Investors

Investment managers reporting LSTA on Form 13F

Holder	Shares	% of company	Change vs last qtr	Held since	% of their book
DI Deeter Investments LLP	118.9K	1.32%	−245.6K (−67.4%)	Q1 '26	0.1%
Shares held by quarter Peak holding364.5K (Q1'26) Change over 8 quarters+118.9K Share of the company1.320% Deeter Investments LLP's full portfolio →
VC Vanguard Capital Management LLC	278.8K	3.09%	+7.0K (+2.6%)	2022	0.0%
Shares held by quarter Peak holding278.8K (Q2'26) Change over 8 quarters+278.8K Share of the company3.090% Vanguard Capital Management LLC's full portfolio →

Deeter Investments LLP

118.9K

% of company

1.32%

Change vs last qtr

−245.6K (−67.4%)

Held since

Q1 '26

Vanguard Capital Management LLC

278.8K

% of company

3.09%

Change vs last qtr

+7.0K (+2.6%)

Held since

2022

28 more super investors behind a free account

See every manager holding Lisata Therapeutics Inc, how their position has changed, and how long they've held it.

Institutional Funds

Mutual funds and ETFs reporting LSTA on Form N-PORT; together they hold 3.8% of the company

Fund	Position value	Shares	% of company	% of the fund	As of
VT Vanguard Total Stock Market Index Fund Vanguard Index Funds	$651K	191.4K	2.12%	0.00%	June 30, 2026
VE Vanguard Extended Market Index Fund Vanguard Index Funds	$274K	80.4K	0.89%	0.00%	June 30, 2026

Vanguard Total Stock Market Index Fund

Vanguard Index Funds

Position value

$651K

% of company

2.12%

% of the fund

0.00%

As of

June 30, 2026

Vanguard Extended Market Index Fund

Vanguard Index Funds

Position value

$274K

% of company

0.89%

% of the fund

0.00%

As of

June 30, 2026

10 more funds behind a free account

See every fund holding Lisata Therapeutics Inc and how much of the fund the position is.

Insiders and 5%+ holders

From Forms 3/4/5 and Schedules 13D/G

Holder	Shares	% of company	Change vs last qtr	8 quarters	Held since	% of their book
MD Mazzo David J Insider	311.9K	3.46%	—	—	—	—
Insider holdings come from Form 3/4/5 filings, which are not quarterly. Share of the company3.460% Mazzo David J's insider activity →
AM Azab Mohammad Insider	104.9K	1.16%	—	—	—	—
Insider holdings come from Form 3/4/5 filings, which are not quarterly. Share of the company1.160% Azab Mohammad's insider activity →

Mazzo David J

Insider

311.9K

% of company

3.46%

Change vs last qtr

—

Held since

—

Azab Mohammad

Insider

104.9K

% of company

1.16%

Change vs last qtr

—

Held since

—

9 more holders behind a free account

See every insider and 5%+ holder of Lisata Therapeutics Inc.

Comments